Logo image of ALXO

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Price, Quote, News and Overview

NASDAQ:ALXO - Nasdaq - US00166B1052 - Common Stock - Currency: USD

1.63  -0.17 (-9.44%)

After market: 1.55 -0.08 (-4.91%)

ALXO Quote, Performance and Key Statistics

ALX ONCOLOGY HOLDINGS INC

NASDAQ:ALXO (1/23/2025, 7:24:42 PM)

After market: 1.55 -0.08 (-4.91%)

1.63

-0.17 (-9.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High17.83
52 Week Low1.19
Market Cap85.97M
Shares52.74M
Float41.97M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-17 2020-07-17


ALXO short term performance overview.The bars show the price performance of ALXO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

ALXO long term performance overview.The bars show the price performance of ALXO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALXO is 1.63 USD. In the past month the price increased by 0.62%. In the past year, price decreased by -88.94%.

ALX ONCOLOGY HOLDINGS INC / ALXO Daily stock chart

ALXO Latest News, Press Releases and Analysis

News Image
9 hours ago - Chartmill

Which stocks are gapping on Thursday?

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

News Image
12 hours ago - ALX Oncology

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response...

News Image
a day ago - ALX Oncology

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a...

News Image
a day ago - USA News Group

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

/PRNewswire/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January...

ALXO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 15.88 301.60B
AMGN AMGEN INC 14.46 149.37B
GILD GILEAD SCIENCES INC 20.98 115.80B
VRTX VERTEX PHARMACEUTICALS INC 862.22 113.24B
REGN REGENERON PHARMACEUTICALS 15.29 76.33B
ARGX ARGENX SE - ADR N/A 39.00B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.54B
BNTX BIONTECH SE-ADR N/A 29.43B
ONC BEIGENE LTD-ADR N/A 23.66B
NTRA NATERA INC N/A 22.68B
BIIB BIOGEN INC 8.8 20.94B
SMMT SUMMIT THERAPEUTICS INC N/A 18.18B

About ALXO

Company Profile

ALXO logo image ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 89 full-time employees. The company went IPO on 2020-07-17. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. The company focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. The company also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Company Info

ALX ONCOLOGY HOLDINGS INC

323 Allerton Avenue

South San Francisco CALIFORNIA 94010 US

CEO: Jaume Pons

Employees: 81

Company Website: https://alxoncology.com/

Investor Relations: https://ir.alxoncology.com/

Phone: 16504667125

ALXO FAQ

What is the price of ALXO?

The current price of ALXO is 1.63 USD.


What is the symbol for ALX ONCOLOGY HOLDINGS INC?

The exchange symbol of ALX ONCOLOGY HOLDINGS INC is ALXO and it is listed on the Nasdaq exchange.


On which exchange is ALXO listed?

ALXO is listed on the Nasdaq exchange.


Is ALXO a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ALXO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ALXO.


Does ALXO pay dividends?

ALXO does not pay a dividend.


What is the Price/Earnings (PE) ratio of ALXO?

ALXO does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.98).


What is the Short Interest ratio of ALXO?

The outstanding short interest for ALXO is 18.11% of its float.


ALXO Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ALXO. When comparing the yearly performance of all stocks, ALXO is a bad performer in the overall market: 93.86% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALXO Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALXO. Both the profitability and financial health of ALXO have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALXO Financial Highlights

Over the last trailing twelve months ALXO reported a non-GAAP Earnings per Share(EPS) of -2.98. The EPS increased by 16.53% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -81.39%
ROE -110.49%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%53.23%
Sales Q2Q%N/A
EPS 1Y (TTM)16.53%
Revenue 1Y (TTM)N/A

ALXO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 77% to ALXO. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners85.25%
Ins Owners1.15%
Short Float %18.11%
Short Ratio7.04
Analysts
Analysts76.92
Price Target7.82 (379.75%)
EPS Next Y25.04%
Revenue Next YearN/A